{"name":"Amneal Pharmaceuticals","slug":"amneal","ticker":"AMRX","exchange":"NYSE","domain":"amneal.com","description":"Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.","hq":"Bridgewater, NJ","founded":0,"employees":"8700","ceo":"Chirag Patel","sector":"Generics & Specialty Pharma","stockPrice":12.64,"stockChange":0.32,"stockChangePercent":2.6,"marketCap":"$4.0B","metrics":{"revenue":3018759936,"revenueGrowth":11.5,"grossMargin":37.4,"rdSpend":186175000,"netIncome":72057000,"cash":282029000,"dividendYield":0,"peRatio":57.5,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Xanax patent cliff ($1.3B at risk)","drug":"Xanax","type":"patent_expiry","sentiment":"negative"},{"date":"2025-06-01","label":"Adderall patent cliff ($1.5B at risk)","drug":"Adderall","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Diclofenac Sodium Topical Gel, 1%","genericName":"Diclofenac Sodium Topical Gel, 1%","slug":"diclofenac-sodium-topical-gel-1","indication":"Topical relief of pain and inflammation associated with osteoarthritis and other musculoskeletal conditions","status":"marketed"},{"name":"Voltaren Topical Gel, 1%","genericName":"Voltaren Topical Gel, 1%","slug":"voltaren-topical-gel-1","indication":"Relief of pain, inflammation, and stiffness associated with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Vehicle Diclofenac Sodium Topical Gel","genericName":"Vehicle Diclofenac Sodium Topical Gel","slug":"vehicle-diclofenac-sodium-topical-gel","indication":"Topical treatment of actinic keratosis","status":"phase_3"}]}],"pipeline":[{"name":"Diclofenac Sodium Topical Gel, 1%","genericName":"Diclofenac Sodium Topical Gel, 1%","slug":"diclofenac-sodium-topical-gel-1","phase":"marketed","mechanism":"Diclofenac sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of topical application.","indications":["Topical relief of pain and inflammation associated with osteoarthritis and other musculoskeletal conditions"],"catalyst":""},{"name":"Vehicle Diclofenac Sodium Topical Gel","genericName":"Vehicle Diclofenac Sodium Topical Gel","slug":"vehicle-diclofenac-sodium-topical-gel","phase":"phase_3","mechanism":"Diclofenac sodium works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to reduced inflammation and pain.","indications":["Topical treatment of actinic keratosis"],"catalyst":""},{"name":"Voltaren Topical Gel, 1%","genericName":"Voltaren Topical Gel, 1%","slug":"voltaren-topical-gel-1","phase":"phase_3","mechanism":"Voltaren Topical Gel, 1% works by reducing inflammation and pain through the inhibition of prostaglandin synthesis.","indications":["Relief of pain, inflammation, and stiffness associated with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Amneal Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Amneal Pharmaceuticals reported its fourth quarter and full year 2023 financial results, with net sales of $1.3 billion and adjusted EBITDA of $243 million.","drugName":"","sentiment":"neutral"},{"date":"2023-10-31","type":"deal","headline":"Amneal Pharmaceuticals Acquires Certain Assets from Impax Laboratories","summary":"Amneal Pharmaceuticals acquired certain assets from Impax Laboratories, expanding its portfolio of generic and branded products.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Approves Amneal Pharmaceuticals' Generic Version of Xanax","summary":"The FDA approved Amneal Pharmaceuticals' generic version of Xanax, a widely used anti-anxiety medication.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-01","type":"earnings","source":"simplywall.st","summary":"Amneal Q4 2025 Highlights Shift Toward Higher Value Pharma Segments - simplywall.st","headline":"Amneal Q4 2025 Highlights Shift Toward Higher Value Pharma Segments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQYnZzY010TWpDbERjenVxUHBjX29mc3kxZDQ4OW1LNklRRkg2bk42Tk1CdURDUmo5bE9WY0o0dDJDNE1hMnhxcTRPelQ5T1JqVXRZOHBrMEVSaXB6bFd2bmZFenNSUWxCeHNoZ2JrbG9jTlU4ZVZuWWQyMWZicVhPbHBZV2w3LW45THlGYkZLckpOSW53T2lVLXJUZ3c2c0ZNbFpPd3Z3Qm8?oc=5","date":"2026-02-27","type":"pipeline","source":"TradingView","summary":"Why Amneal (AMRX) Stock Is Trading Lower Today - TradingView","headline":"Why Amneal (AMRX) Stock Is Trading Lower Today","sentiment":"neutral"},{"date":"2026-02-27","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOLXBjVTdfUnlzNmNLdHBtZ0VsUEVsWkxZX3NRSDI1cGh3NjVLMk54aXZEU2NPQXF3ZFJ1d25pai0xTEQxeW1CYVcyTnVkcEx1VlpxbjFTblI1eTJ6czFWdlI0NnlGaUZxamVjdkNLMFBaNnNRWU9JTFFvVDNqM3hma09Wb1RtWkdTdjBN?oc=5","date":"2026-02-18","type":"pipeline","source":"Yahoo Finance","summary":"Amneal Pharmaceuticals, Inc. (AMRX) Added to S&P SmallCap 600 Index, Boosting Investor Visibility - Yahoo Finance","headline":"Amneal Pharmaceuticals, Inc. (AMRX) Added to S&P SmallCap 600 Index, Boosting Investor Visibility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxNRHdQQ1htR2lvTnBMYjlJbW9iSnlQWE1kS3c3aTNyRGlINEwtLUdOUHJERHFLUXRyWnlod3l2S0J4ZVM3Z0RCYTJma0N1WGt2WTNmNW9sNElsSG1SUjM2U2E1S0VMT2pKMG0xZk13bFhlb1h2REFUaGZpSW4wbVdXLVVZeHB2V0tTb01WMU14bXBVZ2V2eElkWGFsd0JNQzVDZHRiM3hIRER1SkpjbUN5X3hlWGtfSWJRak1SaUpPRXlRM0ZXakgxdjAycnR6aEtFWVQyTXpHaGJ6T0lJMWhjYVNvZmFrYUpJVFJmTDlrOV9hNERxQzlNU2FyVzY2VDJXNzFLalJWSGF3TkdRTE15NUZWVE9CcmtHUHJEdU5JdHkwQnRPajcxNXJYUDMxRURrVUlPTXo1QkVRWENEN2ppODRLZjZaUTg?oc=5","date":"2026-01-14","type":"pipeline","source":"MSN","summary":"Truist raises PT on Amneal Pharmaceuticals (AMRX) to $15 from $14 - MSN","headline":"Truist raises PT on Amneal Pharmaceuticals (AMRX) to $15 from $14","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQLXYyQzM0aXFVNm9GNVpsZ2JCX0VSUHJrelJ3cEJITHBoTUJhME05b0lzT29tR2VicHQ0YlRrak9SSTk1dFQwUjU3djdWRW93WUc0Z3VuZXpVcWlIMU53bk5jaldKc1cySlNqYnE5aEhmN2dYSVNheF9GekVfc1YyaDR5VGZaeXBpVVByRU4wVWRiZ3FObkVPZQ?oc=5","date":"2026-01-06","type":"pipeline","source":"Yahoo Finance","summary":"Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Shareholder Returns - Yahoo Finance","headline":"Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Shareholder Returns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNVGxZMDczSklaVTNDNThoUHNoZFRieHVUbExuemVITDhMOENzRGlsbDloSGFRUnVwWTA4Z2dtS2h3b1Zxdld2SUVlZzlxTUU0azdFMUNuMnRlRUwxYk5OdnVrcFdtUjRkM3BENTVBdDJNVnU5dzlVOEg2RVRCaW50T0ltZG5wTkhDemdabVhmbDdOa3JxUHNYZ0lZV25xSkMxNDg2YVhxdTRFTENnLTdGZzBkRG1ZV1dGNkplcHdKM1ZCeTN6Y1gzNFkydU4?oc=5","date":"2025-12-17","type":"pipeline","source":"Seeking Alpha","summary":"Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks - Seeking Alpha","headline":"Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQVW5qa2hUSDUwZ3UxWkdPRVN4bmhmLTVjRnkzYXhXd1pibFUtdjh1ejYwOEFPTzRCZTdCSktFbjc2SmZ1NV84aHF2cHhCVldHUC05eUNDeHNKS005TmFUcmIxTVk0UXpSQUJjVWdBbDM1YXgyaFBOemJFVUc4SXRtY2pNbUlVWTJ3Rm9GU1hKWHh4VEJjYnRna1k3d2gtSWJuUHF5eVRrWF9TQ19neHp4bHhyNWg3dkItRWxieVBGemlpX1Q5ckRueDExZmQxZw?oc=5","date":"2025-10-30","type":"earnings","source":"Investing.com","summary":"Earnings call transcript: Amneal Pharma Q3 2025 beats EPS forecast, stock rises - Investing.com","headline":"Earnings call transcript: Amneal Pharma Q3 2025 beats EPS forecast, stock rises","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPUVlndkRYbUtqV0xaSXI4Mnp4Vl9nTFlWZW1aWEFFcDlJN2RoUzlpSDZ4ZWhfeHhoa1ZlTzRZRmtfcTdRcV93cDBHYTFNcEk3MnBuMnVYSzliNjlKN0ZWX3M3Y291WGw4VlFQeDdTYTF6UllNMkNkMG1YdmpwTUo3NS1kOU8xMlY1OV96VXFMdlI5eHRkQndOMEd0aENiemlma3lmWjRzc3VfUlZ2eDNUUHpsYml1X0dGWlB6UXFQNnp4WGZXaUltdEp4U3NqWkNDWURYbk9ScXNCOFNl?oc=5","date":"2025-09-23","type":"regulatory","source":"Stocktwits","summary":"Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops - Stocktwits","headline":"Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNbkJaOHNKN3FLRHNLbmJCOU9CYVMxRVdpeWk5c2ZfMVZNcmdNeUptVnR2dWdzemItc1FOWXFuX1l1Z0ZoOWMxUWdYUklzQ3QwdUhfY1dNMlQxNy1zX1VnUEtCQ3ZOd0tMS0V2bmFQVjl0U3VHNlJJa3paa0Z0WjdBQkg3UGZlLWRkOTJ2c3Bka2VFVTB5cjhXUlRZZTQ1Nllqd2RoUkxHamp2LXJkTXdyR0RkaWw?oc=5","date":"2025-09-11","type":"pipeline","source":"Seeking Alpha","summary":"Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing (AMRX) - Seeking Alpha","headline":"Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing (AMRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNc2djZmNKNFJIdW9TVFRqTFBJd1ZqZ3R3NUNJdFJNWjl2bUFwNXNnUmFVZ3YzTk8zY0R6TDRENWpCaGRGaVhNTjRVQmtlY2FiaFcwTkdRclRFZC1jM2pQWnoxMmRXMjVVTXVSbGVGY09ySE1DMGpXMU5ISklRbHJ5UjJTLU1zSVZDQUllWkR2blB3dzFQ?oc=5","date":"2025-09-11","type":"patent","source":"Seeking Alpha","summary":"Amneal's generic targeting Jazz Pharma’s Xyrem cleared (AMRX) - Seeking Alpha","headline":"Amneal's generic targeting Jazz Pharma’s Xyrem cleared (AMRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNU0VzaWFZNmNXaklVVFlpbU1XdW9ncWxGcmxGM2hFQ09KQ0Z2TTZtVTlVUkxLY0RYb2ZTRHpGRHBhVWtodlpUVGtpWmI2a3VYQ3Z1cUtGSlJLejlpcU5JR3lmcHFBZ2lWWHpFbERraFJXRkVOVWtqb3otU1pMWklOQUR3QkJWQUdmY0VGa2hIdDVJd3c?oc=5","date":"2025-07-02","type":"pipeline","source":"Yahoo Finance","summary":"Analysts Bullish as Amneal Pharmaceuticals, Inc. (AMRX) Director Sells Over 94K Shares - Yahoo Finance","headline":"Analysts Bullish as Amneal Pharmaceuticals, Inc. (AMRX) Director Sells Over 94K Shares","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-04-28","type":"regulatory","source":"simplywall.st","summary":"Despite recent sales, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders remain the largest stockholders with 49% ownership - simplywall.st","headline":"Despite recent sales, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders remain the largest stockholders with 49% owner","sentiment":"neutral"}],"patents":[{"drugName":"Xanax","drugSlug":"alprazolam","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":1300000000},{"drugName":"Adderall","drugSlug":"amphetamine-and-dextroamphetamine","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":3,"phaseCounts":{"marketed":1,"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Teva Pharmaceutical Industries","Mallinckrodt Pharmaceuticals","Endo International"],"therapeuticFocus":["Respiratory","Dermatology","Pain Management"],"financials":{"source":"sec_edgar","revenue":0,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":0,"period":"2017-12-31"}],"grossProfit":1113308000,"grossProfitHistory":[],"rdSpend":186175000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":72057000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":282029000,"cashHistory":[],"totalAssets":3678280000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":12.64,"previousClose":12.32,"fiftyTwoWeekHigh":15.42,"fiftyTwoWeekLow":6.68,"fiftyTwoWeekRange":"6.685 - 15.42","fiftyDayAverage":13.45,"twoHundredDayAverage":11.14,"beta":1.32,"enterpriseValue":6355567616,"forwardPE":10.7,"priceToBook":-56.18,"priceToSales":1.34,"enterpriseToRevenue":2.1,"enterpriseToEbitda":9.87,"pegRatio":0,"ebitda":644270016,"ebitdaMargin":21.3,"freeCashflow":197065376,"operatingCashflow":339992000,"totalDebt":2689046016,"debtToEquity":45095.5,"currentRatio":2.17,"returnOnAssets":7.3,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":5,"targetMeanPrice":16.8,"targetHighPrice":18,"targetLowPrice":15,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":44,"institutionHeldPercent":49.5,"sharesOutstanding":318999016,"floatShares":185344857,"sharesShort":10840612,"shortRatio":4.96,"shortPercentOfFloat":3.4,"epsTrailing":0.22,"epsForward":1.18,"revenuePerShare":9.63,"bookValue":-0.23,"officers":[{"age":58,"name":"Mr. Chirag K. Patel","title":"Co-Founder, Co-CEO, President & Director"},{"age":53,"name":"Mr. Chintu  Patel R.Ph.","title":"Co-Founder, Co-CEO & Director"},{"age":58,"name":"Mr. Anastasios G. Konidaris","title":"Executive VP & CFO"},{"age":51,"name":"Mr. Jason B. Daly Esq.","title":"Executive VP, Chief Legal Officer & Corporate Secretary"},{"age":47,"name":"Ms. Nikita  Shah","title":"Executive VP & Chief Human Resources Officer"},{"age":59,"name":"Mr. Andrew S. Boyer","title":"Executive VP and Chief Commercial Officer of Generics & Biosciences"},{"age":null,"name":"Mr. Anthony  DiMeo","title":"Head of Investor Relations"},{"age":null,"name":"Mr. Gregory  Sgammato","title":"Senior Vice President of Corporate Development"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.amneal.com","phone":"908 947 3120"}}